3 Value Stocks To Watch In The Utilities Sector

What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices…

What Defines a Value Stock?

A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

The following stocks are considered to be notable value stocks in the utilities sector:

  1. Clearway Energy (NYSE:CWEN) – P/E: 5.61
  2. Enel Chile (NYSE:ENIC) – P/E: 2.74
  3. Genie Energy (NYSE:GNE) – P/E: 7.19

Clearway Energy has reported Q1 earnings per share at $0.0, which has decreased by 100.0% compared to Q4, which was 0.1. Its most recent dividend yield is at 5.09%, which has increased by 0.56% from 4.53% in the previous quarter.

Enel Chile saw a decrease in earnings per share from 0.86 in Q4 to $0.13 now. Most recently, the company reported a dividend yield of 1.41%, which has decreased by 35.63% from last quarter’s yield of 37.04%.

Most recently, Genie Energy reported earnings per share at $0.54, whereas in Q4 earnings per share sat at $0.61. Most recently, the company reported a dividend yield of 1.96%, which has decreased by 0.45% from last quarter’s yield of 2.41%.

These 3 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

Total
0
Shares
Related Posts
Read More

SpringWorks’ Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update

In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQ: SWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which evaluated nirogacestat for the treatment of desmoid tumor (DT) patients that have experienced progres

SWTX